Donor care before pancreatic tissue transplantation

Progress in Transplantation

Volumn 15, Issue 2, 2005, Pages 129-137

  Powner, David J ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLASE;

AGE; BLOOD; BODY MASS; CAUSE OF DEATH; DONOR SELECTION; GRAFT SURVIVAL; HEART ARREST; HUMAN; HYPOTENSION; INTENSIVE CARE UNIT; LENGTH OF STAY; METHODOLOGY; ORGAN PRESERVATION; OUTCOME ASSESSMENT; PANCREAS ISLET TRANSPLANTATION; PANCREAS TRANSPLANTATION; PREDICTION AND FORECASTING; PREOPERATIVE CARE; REVIEW; STATISTICS; TIME; TRANSPLANTATION;

AGE FACTORS; AMYLASES; BODY MASS INDEX; CAUSE OF DEATH; DONOR SELECTION; GRAFT SURVIVAL; HEART ARREST; HUMANS; HYPOTENSION; INTENSIVE CARE UNITS; ISLETS OF LANGERHANS TRANSPLANTATION; LENGTH OF STAY; ORGAN PRESERVATION; OUTCOME ASSESSMENT (HEALTH CARE); PANCREAS TRANSPLANTATION; PREDICTIVE VALUE OF TESTS; PREOPERATIVE CARE; TIME FACTORS; TISSUE AND ORGAN HARVESTING; TISSUE AND ORGAN PROCUREMENT;

EID: 23944491248     PISSN: 15269248     EISSN: None     Source Type: Journal    
DOI: 10.7182/prtr.15.2.c71698w707117g83     Document Type: Review

References (39)

1. Gruessner AC, Sutherland DE. Pancreas transplant outcomes for United States (US) and non-US cases as reported to the United Network for Organ Sharing (UNOS) and the International Pancreas Transplant Registry (IPTR) as of May 2003. Clin Transpl. 2003:21-51.
2. Zaman F, Abreo KD, Levine S, Maley W, Zibari GB. Pancreatic transplantation: Evaluation and management. J Intensive Care Med. 2004;19:127-139.
3. Serup P, Madsen OD, Mandrup-Poulsen T. Islet and stem cell transplantation for treating diabetes. BMJ. 2001;322:29-32.
4. Robertson RP. Islet transplantation as a treatment for diabetes: A work in progress. N Engl J Med. 2004;350:694-705.
5. Markmann JF, Deng S, Desai NM, et al. The use of nonheart- beating donors for isolated pancreatic islet transplantation. Transplantation. 2003;75:1423-1429.
6. Krieger NR, Odorico JS, Heisey DM, et al. Underutilization of pancreas donors. Transplantation. 2003;75:1271-1276.
7. Clayton HA, Swift SM, Turner JM, James RF, Bell PR. Nonheart- beating organ donors: A potential source of islets for transplantation? Transplantation. 2000;69:2094-2098.
8. Kapur S, Bonham CA, Dodson SF, Dvorchik I, Corry RJ. Strategies to expand the donor pool for pancreas transplantation. Transplantation. 1999;67:284-290.
9. Schmid T, Königsrainer A, Steiner E, Koller J, Margreiter R. Do donor age and cold-ischemia time have a detrimental effect on early pancreas-allograft function? Diabetes. 1989;38(suppl 1):4-6.
10. Hesse UJ, Sutherland DER. Influence of serum amylase and plasma glucose levels in pancreas cadaver donors on graft function in recipients. Diabetes. 1989;38(suppl 1):1-3.
11. Douzdjian V, Gugliuzza KG, Fish JC. Multivariate analysis of donor risk factors for pancreas allograft failure after simultaneous pancreas-kidney transplantation. Surgery. 1995; 118:73-81.
12. Gores PF, Gillingham KJ, Dunn DL, Moudry-Munns KC, Najarian JS, Sutherland DE. Donor hyperglycemia as a minor risk factor and immunologic variables as major risk factors for pancreas allograft loss in a multivariate analysis of a single institution's experience. Ann Surg. 1992;215:217-230.
13. Stratta RJ. Donor age, organ import, and cold ischemia: Effect on early outcomes after simultaneous kidney-pancreas transplantation. Transplant Proc. 1997;29:3291-3292.
14. Gruessner AC, Barrou B, Jones J, et al. Donor impact on outcome of bladder-drained pancreas transplants. Transplant Proc. 1993;25:3114-3115.
15. van Houten H, Gooszen HG, van den Akker PJ, et al. Plasma insulin, C-peptide, HbA1c, and plasma glucose levels in organ donors. Transplant Proc. 1990;22:435-436.
16. Masson F, Thicoipe M, Gin H, et al. The endocrine pancreas in brain-dead donors. Transplantation. 1993;56:363-367.
17. Tamsma JT, Schaapherder AFM, van Bronswijk H, et al. Islet cell hormone release immediately after human pancreatic transplantation. Transplantation. 1993;56:1119-1123.
18. Zeng Y, Torre MA, Karrison T, Thistlethwaite JR. The correlation between donor characteristics and the success of human islet isolation. Transplantation. 1994;57:954-958.
19. Lakey JRT, Warnock GL, Rajotte RV, et al. Variables in organ donors that affect the recovery of human islets of Langerhans. Transplantation. 1996;61:1047-1053.
20. Brandhorst D, Hering BJ, Brandhorst H, Federlin K, Bretzel RG. Influence of donor data and organ procurement on human islet isolation. Transplant Proc. 1994;26:592-593.
21. Benhamou PY, Watt PC, Mullen Y, et al. Human islet isolation in 104 consecutive cases. Transplantation. 1994;57: 1804-1810.
22. Fiedor P, Goodman ER, Sung RS, Shimomura K, Kwiatkowski PA, Hardy MA. Factors that can affect cadaveric islet graft function include hemodynamic changes in the donor prior to organ harvest. Transplant Proc. 1996;28:169-170.
23. Powner DJ, Hernandez M. A review of thyroid hormone administration during adult donor care. Prog Transplant. In press.
24. Powner DJ. Factors during donor care that may affect liver transplantation outcome. Prog Transplant. 2004;14:241-249.
25. Bouwman DL, Weaver DW, Walt AJ. Serum amylase and its isoenzymes: A clarification of their implications in trauma. J Trauma. 1984;24:573-578.
26. Vitale GC, Larson GM, Davidson PR, Bouwman DL, Weaver DW. Analysis of hyperamylasemia in patients with severe head injury. J Surg Res. 1987;43:226-233.
27. Bouwman DL, Altshuler J, Weaver DW. Hyperamylasemia: A result of intracranial bleeding. Surgery. 1983;94:318-323.
28. Pezzilli R, Billi P, Barakat B, et al. Serum pancreatic enzymes in patients with coma due to head injury or acute stroke. Int J Clin Lab Res. 1997;27:244-246.
29. Powner DJ, Hendrich A, Lagler RG, Ng RH, Madden RL. Hormonal changes in brain dead patients. Crit Care Med. 1990;18:702-708.
30. Clifton GL, Ziegler MG, Grossman RG. Circulating catecholamines and sympathetic activity after head injury. Neurosurgery. 1981;8:10-13.
31. Yoshida H, Hiraide A, Yoshioka T, Sugimoto T. Transient suppression of pancreatic endocrine function in patients following brain death. Clin Transplant. 1996;10:28-33.
32. Brunicardi FC, Dyen Y, Brostrom L, et al. The circulating hormonal milieu of the endocrine pancreas in healthy individuals, organ donors, and the isolate perfused human pancreas. Pancreas. 2000;21:203-211.
33. AlKharfy KM, Kellum JA, Matzke GR. Unintended immunomodulation: Part I. Effects of common clinical conditions on cytokine biosynthesis. Shock. 2000;13:333-345.
34. Thicoipe M, Favarel-Garrigues JF, Masson F, et al. Endocrine pancreas after brain death: Preliminary results. Transplant Proc. 1991;23:2481-2482.
35. Groeneveld ABJ, Beishuizen A, Visser FC. Insulin: A wonder drug in the critically ill? Crit Care. 2002;6:102-105.
36. van den Berghe G, Wouters PJ, Bouillon R, et al. Outcome benefit of intensive insulin therapy in the critically ill: Insulin dose versus glycemic control. Crit Care Med. 2003;31:359-366.
37. Powner DJ, Kellum JA, Darby JM. Abnormalities in fluids, electrolytes, and metabolism of organ donors. Prog Transplant. 2000;10:88-96.
38. Brown G, Dodek P. Intravenous insulin nomogram improves blood glucose control in the critically ill. Crit Care Med. 2001;29:1714-1719.
39. Schnuelle P, Berger S, de Boer J, Persijn G, van der Woude FJ. Effects of catecholamine application to brain-dead donors on graft survival in solid organ transplantation. Transplantation. 2001;72:455-463.